The effect of sitagliptin on circadian rhythm in blood glucose using CGM (continuous glucose monitoring) in the elderly patients with diabetes

The effect of sitagliptin on circadian rhythm in blood glucose using CGM (continuous glucose monitoring) in the elderly patients with diabetes - The effect of sitagliptin on circadian rhythm in blood glucose using CGM (continuous glucose monitoring) in the elderly patients with diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012174

Enrollment

Registered

2013-11-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

25mg or 50mg of sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) The patients with type 2 diabetes, 70 years of age and older 2) The subjects with poorly-controlled diabetes by: 1. diet and exercise only 2. sulfonylureas with diet and exercise 3. thiazolidinediones with diet and exercise 4. biguanides with diet and exercise 5. alpha-glucosidase inhibitors with diet and exercise 6. insulin therapy with diet and exercise 3) more than 8g/day of estimated sodium intake calculated by the following formula: 0.0585X21.98X((urinary sodium concentration/urinary potassium concentration)X(-2.04Xage+ 14.89XBW(kg)+16.14XBH(cm)-2244.45))0.392)

Exclusion criteria

Exclusion criteria: 1) the patients wiht type 1 diabetes 2) the subjects with severe renal dysfunction: more than 2.5mg/dl of serum creatinine in male, more than 2.0mg/dl of serum creatinine in female 3) the subjects who cannot reduce the dosage of sulfonylureas (using more than 2mg/day of glimepiride, 1.25mg/day of glibenclamide, 40mg of gliclazide 4) the subjects during pregnancy or lactation 5) the subjects in active treatment for hypothyroidism 6) the subjects with severe liver dysfunction: more than 100IU/L of AST and ALT level 7) the subjects already enrolled in other clinical trial 8) the subjects found offensive by attending physicians for this research

Design outcomes

Primary

Measure	Time frame
circadian rhythm in blood glucose using CGM change in HbA1c	—

Secondary

Measure	Time frame
The change in 1) fasting glood glusoce 2) BMI 3) blood pressure 4) urinary sodium concentration 5) serum creatinine 6) plasma glucagon concetration 7) comprehensive geriatric assessment; IADL, Barthel index, MMSE and GDS	—

Countries

Japan

Contacts

Public ContactKen Sugimoto

Osaka University Graduate School of Medicine Geriatri Medicine

sugimoto@geriat.med.osaka-u.ac.jp06-6879-3852

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026